1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPASE)

Details for Australian Patent Application No. 2006321903 (hide)

Owner Novartis AG.

Inventors Wareing, James Richard; Barnes, David; Topiol, Sidney Wolf; Vedananda, Thalaththani Ralalage; Bebernitz, Gregory Raymond; Stams, Travis; Coppola, Gary Mark

Agent Davies Collison Cave

Pub. Number AU-A-2006321903

PCT Pub. Number WO2007/067613

Priority 60/748,491 08.12.05 US

Filing date 6 December 2006

Wipo publication date 14 June 2007

International Classifications

C07D 285/16 (2006.01) Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups

A61K 31/433 (2006.01) - Thiadiazoles

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

Event Publications

26 June 2008 PCT application entered the National Phase

  PCT publication WO2007/067613 Priority application(s): WO2007/067613

10 November 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006321904-I, l , 3-trioxo-l , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors

2006321902-1-orthofluorophenyl substituted 1, 2 , 5-thiazolidinedione derivatives as PTPas inhibitors